NT-proBNP Peptide Levels at Hospital Discharge Predict Whether Heart Failure Patients Receive Optimal Medication Doses | Research

The takeaway

Heart failure patients with persistent fluid congestion (indicated by insufficient NT-proBNP decline during hospitalization) are discharged on lower doses of recommended medications, highlighting a gap in treatment optimization.

ΔNT-proBNP < 30% = lower medication doses
Patients whose natriuretic peptide biomarker didn't improve sufficiently were paradoxically discharged on the lowest doses of life-saving heart failure medications

What the researchers found

Patients with a less than 30% reduction in NT-proBNP during hospitalization (ΔNT-proBNP < 30%) were discharged on significantly lower doses of guideline-directed medical therapy (GDMT) medications. This association was significant regardless of clinical characteristics or in-hospital management. The in-hospital NT-proBNP burden and trajectory, as markers of residual congestion, were directly associated with underutilization of recommended heart failure medications at discharge.

Why it matters

Residual congestion at hospital discharge is one of the strongest predictors of readmission and death in heart failure. Paradoxically, this study shows that the sickest patients — those with the most residual congestion — are discharged on the lowest doses of the medications proven to save their lives. Using NT-proBNP as a guide to treatment optimization before discharge could improve both medication use and patient outcomes.

How the study worked

Prospective observational study of patients hospitalized for acute heart failure with reduced ejection fraction (HFrEF). NT-proBNP levels were measured at admission and discharge. The percentage change in NT-proBNP (ΔNT-proBNP) was calculated and used to stratify patients. Discharge medication doses of titratable GDMT medications were compared across NT-proBNP trajectory groups.

What this study cannot tell us

The abstract appears to be truncated and some statistical details are incomplete. The study design is observational, so it cannot determine whether lower NT-proBNP declines cause lower GDMT dosing or whether both reflect patient frailty and comorbidity burden. Specific sample sizes and complete outcome data are not available from the abstract. The study focused on HFrEF and may not apply to heart failure with preserved ejection fraction.

How to read the evidence

This is a prospective observational study demonstrating an association between NT-proBNP trajectory and medication dosing at discharge. While the association is clinically important, the observational design cannot establish causation, and the abstract lacks complete statistical details.

When this study was published

Published in 2026, this study addresses an ongoing challenge in heart failure quality of care using the natriuretic peptide biomarker that has been central to cardiology practice for over two decades.

The bigger picture

NT-proBNP is one of the most widely used peptide biomarkers in cardiology, and its role continues to expand from diagnosis to treatment guidance. This study adds treatment optimization at discharge to its clinical utility. As heart failure management moves toward biomarker-guided therapy, NT-proBNP trajectories during hospitalization could become standard decision-making tools — not just for diagnosis, but for ensuring patients leave the hospital on the best possible medication regimen.

Questions still open

Would a protocol requiring NT-proBNP-guided medication titration before discharge improve heart failure outcomes?
Is the lower GDMT dosing in persistent congestion patients driven by physician caution, hemodynamic instability, or other clinical factors?
Could combining NT-proBNP monitoring with other biomarkers improve identification of patients at highest risk for treatment underutilization?

Common questions

What is NT-proBNP and why do doctors measure it in heart failure?

NT-proBNP (N-terminal pro-B-type natriuretic peptide) is a fragment of a peptide hormone released by heart muscle cells when they're stretched by excess fluid — essentially, it's a blood test that measures how hard the heart is working. Higher levels indicate more fluid overload and heart stress. Doctors use it to diagnose heart failure, monitor treatment effectiveness, and predict which patients are at highest risk for complications.

Why are the sickest heart failure patients getting lower medication doses?

This study found that patients whose NT-proBNP levels didn't drop much during hospitalization — indicating ongoing fluid congestion — were sent home on lower doses of recommended heart failure medications. This likely happens because these patients may have low blood pressure or kidney problems that make doctors hesitant to increase doses. However, it creates a paradox: the patients who most need aggressive treatment are getting the least, potentially contributing to readmissions and worse outcomes.

Read the original research

Impact of Predischarge NT-proBNP on Treatment Optimisation in Acute Heart Failure.

International journal of molecular sciences, 27(2)

View on PubMed ↗Publisher’s paper ↗

Citation

Polovina, Marija; Tomić, Milenko; Janković, Milica; Civrić, Danka; Stojićević, Andrea; Stanković, Stefan; Pejović, Teodora; Viduljević, Mihajlo; Krljanac, Gordana; Ašanin, Milika; Stanković, Sanja; Seferović, Petar M. (2026). Impact of Predischarge NT-proBNP on Treatment Optimisation in Acute Heart Failure.. International journal of molecular sciences, 27(2). https://doi.org/10.3390/ijms27021028